Investment Analysts’ Recent Ratings Changes for DexCom (DXCM)

A number of firms have modified their ratings and price targets on shares of DexCom (NASDAQ: DXCM) recently:

• 7/31/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen.
• 7/31/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $94.00 price target on the stock.
• 7/31/2026 – DexCom had its “overweight” rating reaffirmed by Piper Sandler. They now have a $95.00 price target on the stock, up from $88.00.
• 7/31/2026 – DexCom was given a new $105.00 price target by Robert W. Baird.
• 7/31/2026 – DexCom had its “buy” rating reaffirmed by Citigroup Inc..
• 7/31/2026 – DexCom had its “buy” rating reaffirmed by BTIG Research. They now have a $90.00 price target on the stock, up from $80.00.
• 7/31/2026 – DexCom was given a new $93.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 7/31/2026 – DexCom was given a new $95.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Wells Fargo & Company from $85.00 to $90.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – DexCom had its price target raised by Benchmark Co. from $77.00 to $82.00. They now have a “buy” rating on the stock.
• 7/28/2026 – DexCom was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 7/28/2026 – DexCom was given a new $96.00 price target by UBS Group AG. They now have a “buy” rating on the stock.
• 7/28/2026 – DexCom had its “buy” rating reaffirmed by UBS Group AG. They now have a $96.00 price target on the stock.
• 7/16/2026 – DexCom had its price target raised by Truist Financial Corporation from $80.00 to $87.00. They now have a “buy” rating on the stock.
• 7/15/2026 – DexCom had its price target raised by Mizuho from $85.00 to $90.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – DexCom was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/23/2026 – DexCom had its “buy” rating reaffirmed by Benchmark Co..
• 6/23/2026 – DexCom is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $86.00 price target on the stock.
• 6/15/2026 – DexCom had its “overweight” rating reaffirmed by Piper Sandler. They now have a $88.00 price target on the stock, up from $75.00.
• 6/10/2026 – DexCom was given a new $95.00 price target by UBS Group AG.
• 6/10/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen. They now have a $95.00 price target on the stock, up from $75.00.
• 6/9/2026 – DexCom was given a new $85.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 6/8/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $91.00 price target on the stock.
• 6/5/2026 – DexCom was given a new $90.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 6/1/2026 – DexCom had its “hold (c-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,506 shares of company stock valued at $7,205,258. Insiders own 0.28% of the company’s stock.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.